tirzepatide for heart failure with preserved ejection fraction and obesity | NEJM Tirzepatide reduces congestive heart failure
Pay in 4 interest-free payments of $7.10 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
Tirzepatide reduces congestive heart failure events Tirzepatide for Heart Failure in Patients with Obesity NEJM Another "Positive" Heart Failure Trial that Falls Short 60 Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Read the full trial Tirzepatide benefits obese HFpEF patients with and without type 2 diabetes VisualAbstract: Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity 2 Minute Medicine
Store: www.allread.ai · Domain: www.allread.ai



























